<DOC>
	<DOCNO>NCT02622113</DOCNO>
	<brief_summary>This extension study design evaluate safety efficacy Canagliflozin ( TA-7284 ) combination Insulin patient type 2 Diabetes Mellitus . The extension study extension double-blind study 16 week ( TA-7284-11 )</brief_summary>
	<brief_title>Long-Term Safety Study Canagliflozin ( TA-7284 ) Combination With Insulin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This open-label extension study evaluate safety efficacy Canagliflozin ( TA-7284 ) combination insulin Japanese patient Type 2 diabetes mellitus , optimally control diet exercise . The patient enroll double-blind study 16 week receive TA-7284 100mg orally 36 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients complete week 16 assessment doubleblind study ( TA728411 ) Patients hereditary glucosegalactose malabsorption primary renal glucosuria Patients severe diabetic complication ( proliferative diabetic retinopathy , stage 4 nephropathy , serious diabetic neuropathy ) Patients serious renal hepatic disease Patients excessive alcohol addict Patients pregnant , lactate probably pregnant patient patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>